The Pharmacy Compounding Working Group
The Board has also created, empaneled, and charged a Pharmacy
Compounding Working Group to conduct a comprehensive review of
all aspects of compounding pharmacy regulation
including (1) whether and to what extent changes are needed in
either or both of the North Carolina Pharmacy Practice Act and
Board of Pharmacy rules governing compounding pharmacy;
(2) whether and to what extent United States Pharmacopeia
Chapter <797> standards should be specifically incorporated
into state law; (3) whether and to what extent North Carolina
law should mandate or recognize any form of “accreditation”
for compounding pharmacies; (4) whether and to what extent
changes are needed in Board investigator training or inspection
methods with respect to compounding pharmacies; and
(5) what particular issues, if any, with respect to out-of-state
compounding pharmacies, require different or additional regulatory
approaches. Each of these broad topics will encompass
numerous subsidiary issues. The working group will provide a
report and recommendation to the full Board on these issues.
Quoted from North Carolina Board of Pharmacy January 2013 Newsletter found here
The Board has also created, empaneled, and charged a Pharmacy
Compounding Working Group to conduct a comprehensive review of
all aspects of compounding pharmacy regulation
including (1) whether and to what extent changes are needed in
either or both of the North Carolina Pharmacy Practice Act and
Board of Pharmacy rules governing compounding pharmacy;
(2) whether and to what extent United States Pharmacopeia
Chapter <797> standards should be specifically incorporated
into state law; (3) whether and to what extent North Carolina
law should mandate or recognize any form of “accreditation”
for compounding pharmacies; (4) whether and to what extent
changes are needed in Board investigator training or inspection
methods with respect to compounding pharmacies; and
(5) what particular issues, if any, with respect to out-of-state
compounding pharmacies, require different or additional regulatory
approaches. Each of these broad topics will encompass
numerous subsidiary issues. The working group will provide a
report and recommendation to the full Board on these issues.
Quoted from North Carolina Board of Pharmacy January 2013 Newsletter found here
No comments:
Post a Comment